{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:56Z","timestamp":1740163376979,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13555-024-01179-z","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T04:01:27Z","timestamp":1716782487000},"page":"1587-1597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03930186","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Masatoshi","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Deignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Amouzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/1346-8138.16423","volume":"49","author":"H Torii","year":"2022","unstructured":"Torii H, Kishimoto M, Tanaka M, Noguchi H, Chaudhari S. Patient perceptions of psoriatic disease in Japan: results from the Japanese subgroup of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. J Dermatol. 2022;49:818\u201328.","journal-title":"J Dermatol"},{"key":"1179_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/1346-8138.13829","volume":"44","author":"M Ohtsuki","year":"2017","unstructured":"Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017;44:873\u201384.","journal-title":"J Dermatol"},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","volume":"86","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L, Papp K, Leonardi C, Pariser D, Green L, Bhatia N, et al. Efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022;86:77\u201385.","journal-title":"J Am Acad Dermatol"},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/jdv.18689","volume":"37","author":"U Mrowietz","year":"2023","unstructured":"Mrowietz U, Barker J, Conrad C, Jullien D, Gisondi P, Flower A, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas, and impaired quality of life: results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37:348\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1179_CR7","unstructured":"Otezla Japan [package insert]. Tokyo, Japan: Celgene; 2019 September 2019."},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s13555-022-00747-5","volume":"12","author":"Y Okubo","year":"2022","unstructured":"Okubo Y, Takahashi H, Hino R, Endo K, Kikuchi S, Ozeki Y, et al. Efficacy and safety of apremilast in the treatment of patients with mild-to-moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open-label, single-arm study. Dermatol Ther (Heidelb). 2022;12:1469\u201380.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82:117\u201322.","journal-title":"J Am Acad Dermatol"},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaad.2022.10.041","volume":"88","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Papp K, Pariser D, Bhatia N, Sofen H, Albrecht L, et al. Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. J Am Acad Dermatol. 2023;88:430\u20133.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01179-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01179-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01179-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:04:33Z","timestamp":1718197473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01179-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01179-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masatoshi Abe: Celgene and Maruho \u2013 consultant, paid speaker, research grant, and\/or participated in clinical trials. Yukari Okubo<b>:<\/b> Eisai, Maruho, Shiseido, and Torii \u2013 research grants; AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Novartis Pharma, Pfizer, Sanofi, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii, and UCB \u2013 honoraria; AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen Pharma, LEO Pharma, Maruho, Pfizer, Sun Pharma, and UCB \u2013 clinical trials. Hidetoshi Takahashi<b>:<\/b> AbbVie, Amgen Inc., Eli Lilly, Janssen, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Novartis, Sanofi, Sato Pharmaceutical, Sun Pharma, Taiho Pharmaceutical, Torii, and UCB \u2013 honoraria. Koki Endo: Nothing to disclose. Siddharth Chaudhari<b>:<\/b> Amgen K.K. \u2013 employment. Cynthia Deignan and Hamid Amouzadeh: Amgen Inc. \u2013 employees and stockholders. Ryosuke Hino: AbbVie, Amgen, Celgene, Eli Lilly, Janssen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Novartis Pharma, Sanofi, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii Pharma, and UCB Pharma \u2013 honoraria; Amgen, Celgene, Eli Lilly, LEO Pharma, Maruho, Otsuka Pharma, and Sanofi \u2013 clinical trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the institutional review board\/ethics committee before commencement and conducted in compliance with Good Clinical Practice, the International Council for Harmonisation Guideline E6, the Declaration of Helsinki, and applicable regulatory requirements. Patients provided written informed consent before study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}